234 related articles for article (PubMed ID: 24603303)
1. ASC amino-acid transporter 2 (ASCT2) as a novel prognostic marker in non-small cell lung cancer.
Shimizu K; Kaira K; Tomizawa Y; Sunaga N; Kawashima O; Oriuchi N; Tominaga H; Nagamori S; Kanai Y; Yamada M; Oyama T; Takeyoshi I
Br J Cancer; 2014 Apr; 110(8):2030-9. PubMed ID: 24603303
[TBL] [Abstract][Full Text] [Related]
2. Prognostic significance of amino-acid transporter expression (LAT1, ASCT2, and xCT) in surgically resected tongue cancer.
Toyoda M; Kaira K; Ohshima Y; Ishioka NS; Shino M; Sakakura K; Takayasu Y; Takahashi K; Tominaga H; Oriuchi N; Nagamori S; Kanai Y; Oyama T; Chikamatsu K
Br J Cancer; 2014 May; 110(10):2506-13. PubMed ID: 24762957
[TBL] [Abstract][Full Text] [Related]
3. Clinicopathological significance of ASC amino acid transporter-2 expression in pancreatic ductal carcinoma.
Kaira K; Sunose Y; Arakawa K; Sunaga N; Shimizu K; Tominaga H; Oriuchi N; Nagamori S; Kanai Y; Oyama T; Takeyoshi I
Histopathology; 2015 Jan; 66(2):234-43. PubMed ID: 24845232
[TBL] [Abstract][Full Text] [Related]
4. Clinical associations between ASCT2 and p‑mTOR in the pathogenesis and prognosis of epithelial ovarian cancer.
Guo H; Xu Y; Wang F; Shen Z; Tuo X; Qian H; Wang H; Wang K
Oncol Rep; 2018 Dec; 40(6):3725-3733. PubMed ID: 30272366
[TBL] [Abstract][Full Text] [Related]
5. Clinical significance of coexpression of L-type amino acid transporter 1 (LAT1) and ASC amino acid transporter 2 (ASCT2) in lung adenocarcinoma.
Yazawa T; Shimizu K; Kaira K; Nagashima T; Ohtaki Y; Atsumi J; Obayashi K; Nagamori S; Kanai Y; Oyama T; Takeyoshi I
Am J Transl Res; 2015; 7(6):1126-39. PubMed ID: 26279756
[TBL] [Abstract][Full Text] [Related]
6. Clinicopathological significance of LAT1 and ASCT2 in patients with surgically resected esophageal squamous cell carcinoma.
Honjo H; Kaira K; Miyazaki T; Yokobori T; Kanai Y; Nagamori S; Oyama T; Asao T; Kuwano H
J Surg Oncol; 2016 Mar; 113(4):381-9. PubMed ID: 26936531
[TBL] [Abstract][Full Text] [Related]
7. Expression of Amino Acid Transporters (LAT1 and ASCT2) in Patients with Stage III/IV Laryngeal Squamous Cell Carcinoma.
Nikkuni O; Kaira K; Toyoda M; Shino M; Sakakura K; Takahashi K; Tominaga H; Oriuchi N; Suzuki M; Iijima M; Asao T; Nishiyama M; Nagamori S; Kanai Y; Oyama T; Chikamatsu K
Pathol Oncol Res; 2015 Sep; 21(4):1175-81. PubMed ID: 26024742
[TBL] [Abstract][Full Text] [Related]
8. ASCT2 overexpression is associated with poor survival of OSCC patients and ASCT2 knockdown inhibited growth of glutamine-addicted OSCC cells.
Luo Y; Li W; Ling Z; Hu Q; Fan Z; Cheng B; Tao X
Cancer Med; 2020 May; 9(10):3489-3499. PubMed ID: 32162845
[TBL] [Abstract][Full Text] [Related]
9. The glutamine transporter ASCT2 (SLC1A5) promotes tumor growth independently of the amino acid transporter LAT1 (SLC7A5).
Cormerais Y; Massard PA; Vucetic M; Giuliano S; Tambutté E; Durivault J; Vial V; Endou H; Wempe MF; Parks SK; Pouyssegur J
J Biol Chem; 2018 Feb; 293(8):2877-2887. PubMed ID: 29326164
[TBL] [Abstract][Full Text] [Related]
10. Prognostic significance of L-type amino acid transporter 1 (LAT1) expression in patients with ovarian tumors.
Kaira K; Nakamura K; Hirakawa T; Imai H; Tominaga H; Oriuchi N; Nagamori S; Kanai Y; Tsukamoto N; Oyama T; Asao T; Minegishi T
Am J Transl Res; 2015; 7(6):1161-71. PubMed ID: 26279759
[TBL] [Abstract][Full Text] [Related]
11. Proteomic profiling of breast cancer metabolism identifies SHMT2 and ASCT2 as prognostic factors.
Bernhardt S; Bayerlová M; Vetter M; Wachter A; Mitra D; Hanf V; Lantzsch T; Uleer C; Peschel S; John J; Buchmann J; Weigert E; Bürrig KF; Thomssen C; Korf U; Beissbarth T; Wiemann S; Kantelhardt EJ
Breast Cancer Res; 2017 Oct; 19(1):112. PubMed ID: 29020998
[TBL] [Abstract][Full Text] [Related]
12. Targeting ASCT2-mediated glutamine uptake blocks prostate cancer growth and tumour development.
Wang Q; Hardie RA; Hoy AJ; van Geldermalsen M; Gao D; Fazli L; Sadowski MC; Balaban S; Schreuder M; Nagarajah R; Wong JJ; Metierre C; Pinello N; Otte NJ; Lehman ML; Gleave M; Nelson CC; Bailey CG; Ritchie W; Rasko JE; Holst J
J Pathol; 2015 Jul; 236(3):278-89. PubMed ID: 25693838
[TBL] [Abstract][Full Text] [Related]
13. NDRG2 ablation reprograms metastatic cancer cells towards glutamine dependence
Ding M; Bu X; Li Z; Xu H; Feng L; Hu J; Wei X; Gao J; Tao Y; Cai B; Liu Y; Qu X; Shen L
Int J Biol Sci; 2020; 16(16):3100-3115. PubMed ID: 33162818
[No Abstract] [Full Text] [Related]
14. ASCT2 silencing regulates mammalian target-of-rapamycin growth and survival signaling in human hepatoma cells.
Fuchs BC; Finger RE; Onan MC; Bode BP
Am J Physiol Cell Physiol; 2007 Jul; 293(1):C55-63. PubMed ID: 17329400
[TBL] [Abstract][Full Text] [Related]
15. Expression of amino acid transporters (LAT1, ASCT2 and xCT) as clinical significance in hepatocellular carcinoma.
Namikawa M; Kakizaki S; Kaira K; Tojima H; Yamazaki Y; Horiguchi N; Sato K; Oriuchi N; Tominaga H; Sunose Y; Nagamori S; Kanai Y; Oyama T; Takeyoshi I; Yamada M
Hepatol Res; 2015 Sep; 45(9):1014-1022. PubMed ID: 25297701
[TBL] [Abstract][Full Text] [Related]
16. Circular RNA circ-LDLRAD3 serves as an oncogene to promote non-small cell lung cancer progression by upregulating SLC1A5 through sponging miR-137.
Xue M; Hong W; Jiang J; Zhao F; Gao X
RNA Biol; 2020 Dec; 17(12):1811-1822. PubMed ID: 32658600
[TBL] [Abstract][Full Text] [Related]
17. Deletion of Amino Acid Transporter ASCT2 (SLC1A5) Reveals an Essential Role for Transporters SNAT1 (SLC38A1) and SNAT2 (SLC38A2) to Sustain Glutaminolysis in Cancer Cells.
Bröer A; Rahimi F; Bröer S
J Biol Chem; 2016 Jun; 291(25):13194-205. PubMed ID: 27129276
[TBL] [Abstract][Full Text] [Related]
18. Overexpression of the neutral amino acid transporter ASCT2 in human colorectal adenocarcinoma.
Witte D; Ali N; Carlson N; Younes M
Anticancer Res; 2002; 22(5):2555-7. PubMed ID: 12529963
[TBL] [Abstract][Full Text] [Related]
19. Targeting of glutamine transporter ASCT2 and glutamine synthetase suppresses gastric cancer cell growth.
Ye J; Huang Q; Xu J; Huang J; Wang J; Zhong W; Chen W; Lin X; Lin X
J Cancer Res Clin Oncol; 2018 May; 144(5):821-833. PubMed ID: 29435734
[TBL] [Abstract][Full Text] [Related]
20. GLUT1 and ASCT2 as Predictors for Prognosis of Hepatocellular Carcinoma.
Sun HW; Yu XJ; Wu WC; Chen J; Shi M; Zheng L; Xu J
PLoS One; 2016; 11(12):e0168907. PubMed ID: 28036362
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
